Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt

Warren Buffett famously said, ‘Volatility is far from synonymous with risk.’ When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. We note that Harvard Bioscience, Inc. (NASDAQ:HBIO) does have debt on its balance sheet. But the more important question is: how much risk is that debt creating?

What Risk Does Debt Bring?

Debt assists a business until the business has trouble paying it off, either with new capital or with free cash flow. In the worst case scenario, a company can go bankrupt if it cannot pay its creditors. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Of course, debt can be an important tool in businesses, particularly capital heavy businesses. The first step when considering a company’s debt levels is to consider its cash and debt together.

Check out our latest analysis for Harvard Bioscience

What Is Harvard Bioscience’s Debt?

You can click the graphic below for the historical numbers, but it shows that Harvard Bioscience had US$44.4m of debt in June 2020, down from US$55.4m, one year before. However, it also had US$2.63m in cash, and so its net debt is US$41.8m.

debt-equity-history-analysis
NasdaqGM:HBIO Debt to Equity History September 1st 2020

How Strong Is Harvard Bioscience’s Balance Sheet?

Zooming in on the latest balance sheet data, we can see that Harvard Bioscience had liabilities of US$22.7m due within 12 months and liabilities of US$52.0m due beyond that. Offsetting these obligations, it had cash of US$2.63m as well as receivables valued at US$14.7m due within 12 months. So it has liabilities totalling US$57.3m more than its cash and near-term receivables, combined.

While this might seem like a lot, it is not so bad since Harvard Bioscience has a market capitalization of US$130.5m, and so it could probably strengthen its balance sheet by raising capital if it needed to. However, it is still worthwhile taking a close look at its ability to pay off debt. When analysing debt levels, the balance sheet is the obvious place to start. But ultimately the future profitability of the business will decide if Harvard Bioscience can strengthen its balance sheet over time. So if you’re focused on the future you can check out this free report showing analyst profit forecasts.

Over 12 months, Harvard Bioscience made a loss at the EBIT level, and saw its revenue drop to US$105m, which is a fall of 12%. That’s not what we would hope to see.

Caveat Emptor

Not only did Harvard Bioscience’s revenue slip over the last twelve months, but it also produced negative earnings before interest and tax (EBIT). Indeed, it lost US$1.7m at the EBIT level. Considering that alongside the liabilities mentioned above does not give us much confidence that company should be using so much debt. Quite frankly we think the balance sheet is far from match-fit, although it could be improved with time. We would feel better if it turned its trailing twelve month loss of US$8.2m into a profit. So in short it’s a really risky stock. When analysing debt levels, the balance sheet is the obvious place to start. But ultimately, every company can contain risks that exist outside of the balance sheet. For example, we’ve discovered 3 warning signs for Harvard Bioscience that you should be aware of before investing here.

At the end of the day, it’s often better to focus on companies that are free from net debt. You can access our special list of such companies (all with a track record of profit growth). It’s free.

Promoted
If you decide to trade Harvard Bioscience, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account.


This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020


Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.